Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 45INDUSTRY 39NIH 16NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 90Other hematologic neoplasm 58Breast 42CNS 31Sarcoma 24Plasma cell 20Genitourinary 8Myeloid 6Gynecologic 4Classical hematology 4Dermatologic 3Other neoplasm 2Thoracic 1Other solid neoplasm 1Endocrine 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 40Carboplatin 40Paclitaxel 34Radiotherapy 32Docetaxel 19Pemetrexed 17Gemcitabine 17Etoposide 17Bevacizumab 11Radiosurgery 9Magnetic Resonance Spectroscopy 9Ramucirumab 8durvalumab 7Taxes 7Cetuximab 7pembrolizumab 6Specimen Handling 6Erlotinib Hydrochloride 6Irinotecan 5Gene Expression Profiling 5Filgrastim 5cediranib 4Vinorelbine 4Polymerase Chain Reaction 4Neoadjuvant Therapy 4Fluorodeoxyglucose F18 4Chemotherapy, Adjuvant 4Amplified Fragment Length Polymorphism Analysis 4tremelimumab 3osimertinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Cyclophosphamide × Thoracic × Clear all
NCT00828009 2023-07-07

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Eastern Cooperative Oncology Group

Phase 2 Completed
70 enrolled 10 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡